sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group's Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its position concerning Avadel Pharmaceuticals plc under the Irish Takeover Panel's Form 8.3. The disclosure was made on December 2, 2025, showing Vanguard's ownership of 5,582,423 ordinary shares, equivalent to 5.73% of the company's securities.
This form details the interests and short positions Vanguard holds in Avadel Pharmaceuticals' securities. The shares are priced at $0.01 each. The filing also includes purchase and sale activities, noting the purchase of 784 shares and the sale of 138 shares, both at a rate of $21.35 per share.
No cash-settled or stock-settled derivatives transactions were listed, and The Vanguard Group reported no indemnity or option arrangements connected to these securities. There are also no agreements concerning voting rights or future transactions involving Avadel's securities.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.